BAY 3018250
Alternative Names: Anti-a2AP; BAY-3018250Latest Information Update: 27 Aug 2024
At a glance
- Originator Bayer
- Class Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Antiplasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thrombosis
- Phase I Pulmonary embolism; Stroke
Most Recent Events
- 20 Aug 2024 Bayer plans a phase I trial in healthy volunteers in August 2024 (IV) (NCT06562985)
- 20 Feb 2024 Phase-II clinical trials in Thrombosis (unspecified route) (NCT06149520)
- 15 Jan 2024 Phase-II clinical trials in Thrombosis in France (unspecified route) (NCT06149520)